Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Seront

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Oncology (Toronto, Ont.)|January 4, 2020
Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic reviewJ Pierrard, E Seront
Clinical Colorectal Cancer|February 7, 2012
Liver-directed therapies: does it make sense in the current therapeutic strategy for patients with confined liver colorectal metastases?E Seront, M Van den Eynde
Clinical and Experimental Dermatology|February 28, 2017
Palmar fasciitis and polyarthritis, a rare paraneoplastic syndrome related to ovarian cancerC van Marcke, E Seront, C Docquier, et al.
British Journal of Cancer|August 31, 2013
PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activationE Seront, A Pinto, C Bouzin, et al.
European Journal of Internal Medicine|October 14, 2008
About two intra-aortic massesE Seront, G de Saint-Hubert, J P Gilbeau, et al.
Acta Clinica Belgica|February 18, 2012
New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-reportE Seront, F Mazzeo, M Mano, et al.
British Journal of Cancer|October 26, 2013
Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumoursE Seront, R Boidot, C Bouzin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2012
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkersE Seront, S Rottey, B Sautois, et al.
ESMO Open|May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)R Galot, C Le Tourneau, L Licitra, et al.
ESMO Open|November 10, 2022
Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the futureT Geukens, M Brandão, A Laenen, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Oncology (Toronto, Ont.)|January 4, 2020
Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic reviewJ Pierrard, E Seront
Clinical Colorectal Cancer|February 7, 2012
Liver-directed therapies: does it make sense in the current therapeutic strategy for patients with confined liver colorectal metastases?E Seront, M Van den Eynde
Clinical and Experimental Dermatology|February 28, 2017
Palmar fasciitis and polyarthritis, a rare paraneoplastic syndrome related to ovarian cancerC van Marcke, E Seront, C Docquier, et al.
British Journal of Cancer|August 31, 2013
PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activationE Seront, A Pinto, C Bouzin, et al.
European Journal of Internal Medicine|October 14, 2008
About two intra-aortic massesE Seront, G de Saint-Hubert, J P Gilbeau, et al.
Acta Clinica Belgica|February 18, 2012
New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-reportE Seront, F Mazzeo, M Mano, et al.
British Journal of Cancer|October 26, 2013
Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumoursE Seront, R Boidot, C Bouzin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2012
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkersE Seront, S Rottey, B Sautois, et al.
ESMO Open|May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)R Galot, C Le Tourneau, L Licitra, et al.
ESMO Open|November 10, 2022
Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the futureT Geukens, M Brandão, A Laenen, et al.
Pageof 2